MONDAY, Oct. 16, 2023 (HealthDay News) -- Differences in outcomes by race and ethnicity exist for men with nonmetastatic castration-resistant prostate cancer (nmCRPC); however, equal access to care appears to lessen these disparities, according to a study published online Oct. 11 in JAMA Network Open.
Kelli M. Rasmussen, from the University of Utah in Salt Lake City, and colleagues examined clinical outcomes by race and ethnicity in patients with nmCRPC within the U.S. Veterans Health Administration (2006 to 2021). The analysis included 12,992 veterans followed for a mean of 4.3 years. Time from the landmark period to death or metastasis was the primary outcome, while overall survival was the secondary outcome.
The researchers found that median time elapsed from nmCRPC to metastasis or death was 5.96 years for Black patients, 5.62 years for Hispanic patients, 4.11 years for White patients, and 3.59 years for other patients. Median unadjusted overall survival was 6.26 years overall but was from 8.36 years for Black patients, 8.56 years for Hispanic patients, 5.48 years for White patients, and 4.48 years for other patients.
"The findings of this study suggest that the availability of equal-access care may reduce and even reverse racial and ethnic disparities in patients," the authors write. "In addition, Black and Hispanic men may have considerably improved outcomes when treated in an equal-access setting."
Several authors disclosed ties to the pharmaceutical industry.
(0) comments
Welcome to the discussion.
Log In
Keep it clean. Please avoid obscene, vulgar, lewd, racist or sexual language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't threaten. Threats of harming another person will not be tolerated.
Be truthful. Don't knowingly lie about anyone or anything.
Be nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be proactive. Use the "Report" link on each comment to let us know of abusive posts.
Share with us. We'd love to hear eyewitness accounts, the history behind an article.